1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Croatia Pharmaceuticals and Healthcare Report Q4 2016

Croatia Pharmaceuticals and Healthcare Report Q4 2016

  • September 2016
  • -
  • Business Monitor International
  • -
  • 78 pages

Includes 3 FREE quarterly updates

BMI View:

Continued political instability coupled with a bleak economic outlook will continue to repressthe pharmaceutical and healthcare sectors in Croatia. Necessary austerity measures will impose furtherbarriers towards growth and reduce the use of high-value patented drugs, highlighting minimal revenueearning opportunities for multinational pharmaceutical firms.

Headline Expenditure Projections


- Pharmaceuticals: HRK6.73bn (USD860mn) in 2015 to HRK6.70bn (USD930mn) in 2016; - 0.3% inlocal currency and 8.3% in US dollar terms. Forecast in US dollar terms revised upward.

- Healthcare: HRK26.2bn (USD3.34bn) in 2015 to HRK26.7bn (USD3.70bn) in 2016; 2.0% in localcurrency and 10.8% in US dollar terms. Forecast in US dollar terms revised upward.Risk/Reward IndexDespite its accession to the EU, Croatia offers little in the way of growth prospects over the long term.Croatia recorded a score of 48.4 out of 100 in our Q416 Risk/Reward Index (RRI), making it the 15th mostattractive pharmaceutical market in Central and Eastern Europe. Croatia's RRI score this quarter improvedfrom 46.0 in Q316 but it still remains poor owing to the depreciation of the Croatian kuna against the dollarand our concerns over the country's economic outlook impacting our pharmaceutical sales forecasts.

Table Of Contents

Croatia Pharmaceuticals and Healthcare Report Q4 2016
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (Croatia 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Croatia 2012-2020) 13
Healthcare Market Forecast 14
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Croatia 2012-2020) 16
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Croatia 2012-2020) 16
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Croatia 2012-2020) 16
Prescription Drug Market 17
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Croatia 2012-2020) 19
Patented Drug Market Forecast 20
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Croatia 2012-2020) 21
Generic Drug Market Forecast 22
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Croatia 2012-2020) 23
OTC Medicines Market Forecast 24
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Croatia 2012-2020) 25
Pharmaceutical Trade Forecast 26
Table: Pharmaceutical Trade Data And Forecasts (Croatia 2014-2020) 27
Table: Pharmaceutical Trade Data And Forecasts local currency (Croatia 2014-2020) 27
Industry Risk Reward Index 28
Central And Eastern Europe Risk/Reward Index - Q4 2016 28
Croatia Risk/Reward Index 35
Rewards 35
Risks 36
Regulatory Review 37
Intellectual Property Issues 40
Pricing Regime 41
Table: Profit Margins For Wholesalers 42
Reimbursement Regime 42
Market Overview 45
Healthcare Sector 46
Table: Healthcare Resources (Croatia 2010-2015) 46
Table: Healthcare Personnel (Croatia 2010-2015) 47
Table: Healthcare Activity (Croatia 2010-2015) 47
Table: Reimbursed Drug Expenditure By HZZO (HRKbn) - Equivalent To Final Consumer Prices 48
Research and Development 49
Clinical Trials 50
Epidemiology 51
Table: Cancer Incidence Rates, 2012-2035 53
Competitive Landscape 55
Research-Based Industry 55
Table: Multinational Market Activity 56
Generic Drugmakers 57
Pharmaceutical Distribution 57
Pharmaceutical Retail 58
Company Profile 59
Belupo 59
Jadran Galenski Laboratorij 62
PLIVA 64
Demographic Forecast 67
Table: Population Headline Indicators (Croatia 1990-2025) 68
Table: Key Population Ratios (Croatia 1990-2025) 68
Table: Urban/Rural Population and Life Expectancy (Croatia 1990-2025) 69
Table: Population By Age Group (Croatia 1990-2025) 69
Table: Population By Age Group % (Croatia 1990-2025) 70
Glossary 72
Methodology 74
Pharmaceutical Expenditure Forecast Model 74
Healthcare Expenditure Forecast Model 74
Notes On Methodology 75
Risk/Reward Index Methodology 76
Index Overview 77
Table: Pharmaceutical Risk/Reward Index Indicators 77
Indicator Weightings 78

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.